Children with autoimmune hepatitis receiving standard-of-care therapy demonstrate long-term obesity and linear growth delay
This study demonstrates that children with AIH receiving standard-of-care therapy demonstrate altered growth trajectories, long-term excess weight gain, obesity, and linear growth delay. Young age at diagnosis and >10 mg of daily prednisone at 6 months are predictors for linear growth delay. These data indicate the need to re-evaluate standard treatment algorithms for pediatric AIH in terms of steroid dosing and potential nonsteroid alternatives.
Authors
- Céline Bourdon (ORCID: https://orcid.org/0000-0002-6336-0906)
- Shannon M. Vandriel (ORCID: https://orcid.org/0000-0001-7157-2063)
- Robert Bandsma (ORCID: https://orcid.org/0000-0001-6358-4750)
- Vicky L. Ng (ORCID: https://orcid.org/0000-0002-9998-5692)
- Binita Maya Kamath (ORCID: https://orcid.org/0000-0002-9982-5023)
- Or Steg Saban (ORCID: https://orcid.org/0000-0001-7281-3949)
- Amrita Mundh
- Simon C. Ling (ORCID: https://orcid.org/0000-0002-4223-4601)
- Saher Fatima
Institutions
- Children's Hospital of Philadelphia (US)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- University of Pennsylvania (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1097/hc9.0000000000000624
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00